|
CTC phenotype classifier to identify mCRPC patients (pts) with high genomic instability CTCs and to predict failure of androgen ecreptor signaling (AR Tx) and taxane (T) systemic therapies. |
|
|
Honoraria - Chugai Pharma |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Celgene; Endo Pharmaceuticals; Endocyte; Exelixis; Ferring; Foundation Medicine; Genentech; Janssen; Medivation; OncologySTAT; Palmetto GBA; Pfizer; Sanofi; Takeda; Ventana Medical Systems; WIRB-Copernicus Group |
|
Research Funding - BIND Biosciences (Inst); Exelixis (Inst); Janssen (Inst); Janssen Diagnostics (Inst); Medivation (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Celgene; Endocyte; Exelixis; Ferring; Genentech; Janssen; Pfizer; Sanofi; Takeda; WIRB-Copernicus Group |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
No Relationships to Disclose |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
No Relationships to Disclose |
|
|
Employment - Epic Sciences |
Leadership - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
Patents, Royalties, Other Intellectual Property - Patents Pending |